Substituted imidazo[1,2-a]pyrrolo[1,2-d]pyrazines for treating respiratory syncytial virus infections

摘要

The present invention relates to compounds of formula (I);
its salts, isomers or prodrugs thereof useful in the treatment of viral infections, in particular respiratory syncytial virus (RSV) infections. The present invention also relates to processes for preparing the compounds and intermediates used in their preparation.

主权项

1. A method for modulating respiratory syncytial viral activity in a subject, comprising the step of administering to said subject a compound of formula (I): wherein -------- represents single or double bonds depending on the required valencies of the ring atoms; each Y is CH; X is CH; X1 is selected from O, S, NR6, and C(R6)2 wherein each R6 is independently selected from H, optionally substituted C1-6alkyl, optionally substituted C2-6alkenyl, optionally substituted C2-6alkynyl, optionally substituted C3-8cycloalkyl, optionally substituted heterocyclyl and optionally substituted aryl; X2 is C(R3R4) wherein R3 and R4 are each independently selected from H, optionally substituted C1-6alkyl, optionally substituted C2-6alkenyl, optionally substituted C2-6alkynyl, optionally substituted C3-8cycloalkyl, optionally substituted heterocyclyl and optionally substituted aryl; R1 is optionally substituted C1-6alkyl, optionally substituted C2-6alkenyl, optionally substituted C2-6alkynyl, optionally substituted C3-8cycloalkyl, optionally substituted heterocyclyl or optionally substituted aryl; R2 is H, R8, C(═O)R8, C(═S)R8 or S(O2)R8 wherein R8 is selected from optionally substituted C1-6alkyl, optionally substituted C2-6alkenyl, optionally substituted C2-6alkynyl, N(R6)2, optionally substituted —N(R6)q(R7)qcycloalkyl, optionally substituted —N(R6)q(R7)qheterocyclyl and optionally substituted —N(R6)q(R7)qaryl wherein each R7 is independently selected from optionally substituted C1-6alkyl, optionally substituted C2-6alkenyl, optionally substituted C2-6alkynyl, optionally substituted C3-8cycloalkyl, optionally substituted heterocyclyl or optionally substituted aryl and each q is independently 0 or 1; Y1 is one or more optional substituents, or is absent; Y2 is H or one or more optionally substituted R7; m and n are both 1; p is 2; and wherein the optional substituents are independently selected from the group consisting of R7, R7-R7, (R7)qhalo, (R7)qCN, ═O, (R7)qOR6, (R7)qOCHF2, (R7)qOCF3, (R7)qCHF2, (R7)qCF3, ═S, (R7)qSR6, (R7)qSO3H, (R7)qSO2—R7, (R7)qSO2N(R6)2, (R7)qNO2, (R7)qN(R6)2, (R7)qOC(═O)—R7, (R7)qC(═O)OR6, (R7)qC(═O)R6, (R7)qC(═O)N(R6)2, (R7)qNR6C(═O)—R7, (R7)qNR6SO2R7, (R7)qSi(R7)3 and (R7)qO—Si(R7)3;or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof.